UMGCCC Clinical Trials

  • More About Clinical Trials
  • Deciding to Enroll
  • Questions to Ask
  • For More Information
  • Research
  • Cancer Overviews
  • Treatment Programs
  • Physicians and Staff
ProtocolsBack To Search Instructions
158 protocol(s) meet the specified criteria
Protocol No.TitleStatus
0848RTOGRTOG 0848, A Phase IIR and A Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas AdenocarcinomaOpen
0858GCCVIRTUAL REALITY AND ACUTE PAIN MANAGEMENT FOR CHILDREN: PILOT TESTING OF VIRTUAL REALITY FOR INVASIVE MEDICAL PROCEDURES IN PEDIATRIC ONCOLOGY PATIENTS Open
0920RTOGA PHASE III STUDY OF POSTOPERATIVE RADIATION THERAPY (IMRT) +/- CETUXIMAB FOR LOCALLY-ADVANCED RESECTED HEAD AND NECK CANCEROpen
0924RTOGAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialOpen
1016GCCThe Role of NKT cells in Breast Cancer Patients and Healthy VolunteersOpen
1122GCCObservational Study of hepatic metastasis of colorectal originOpen (affiliates only)
1150GCCA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications.Open
1224GCCPhase II Trial of Low-Dose Whole Brain Radiotherapy with Concurrent Temozolomide and Adjuvant Temozolomide in Patients with Newly-Diagnosed Glioblastoma MultiformeOpen
1227GCCIrreversible electroporation for locally advanced unresectable pancreatic cancer; HP-00052144.Open
1301GCC Postoperative heme oxygenase induction and carbon monoxide production as novel method to assess hepatic regeneration and predict hepatic related morbidity after partial hepatectomy HP-00054854 - Cherif BoutrosOpen (affiliates only)
1304RTOG/NSABP-B-51RTOG1304/NSABP B-51 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyOpen
1306RTOGA RANDOMIZED PHASE II STUDY OF INDIVIDUALIZED COMBINED MODALITY THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC)Open
1314GCCPhase II Trial of Low Dose Whole Pelvic Radiotherapy with Concurrent Neoadjuvant FOLFOX for Patients with Newly Diagnosed T3N0M0, T2N1M0, and T3N1M0 Rectal AdenocarcinomaOpen
1324GCCNeoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients with Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study Open
1344GCCPILOT STUDY OF COMBINED OPTUNE, BEVACIZUMAB, AND HYPOFRACTIONATED STEREOTACTIC IRRADIATION FOR BEVACIZUMAB-NAIIVE, RECURRENT GLIOBLASTOMA Open
1366GCCA PROSPECTIVE STUDY OF NEOADJUVANT NON-STEROIDAL AROMATASE INHIBITORS IN POSTMENOPAUSAL WOMEN WITH OPERABLE HORMONE RECEPTOR-POSITIVE BREAST CANCER TO EVALUATE THE ANTI-PROLIFERATIVE RESPONSE IN OBESE AND OVERWEIGHT PATIENTSOpen
1403GCCAn Umbrella Protocol for Collection of Blood, Tumor Tissue, Lymph Node Specimens, normal breast tissue, effusions CSF fluid and Buccal Samples from Patients with Established or Suspected Breast Malignancy and Normal Subjects, to be used in Laboratory ResearchOpen
1404GCC1404GCC: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line ChemotherapyOpen
1424GCCA Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic SyndromeOpen
1425GCCInhibition of Pim kinases in acute myeloid leukemia Open
1455GCC1455GCC: An Umbrella Protocol for Collection of Blood Samples from Patients Undergoing Craniotomy or Stereotactic Brain Biopsy, to be used in Laboratory ResearchOpen
1456GCC1456GCC: A Phase II trial of reirradiation combined with open label Pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (SCCHN)Open
1495GCC1495GCC: An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Thoracic Malignancies and Normal Subjects, to Be Used in Laboratory ResearchOpen
1504GCCRandomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)Open
15100GCCPragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium TrialOpen
1524GCCA Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer [GO24931]Open
1530GCCA Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of DosesOpen
1532GCC1532GCC: Phase I Study of C6 Ceramide Nanoliposome in Patients with Advanced Solid TumorsOpen
1533GCCA Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer Open
1534GCC A pilot study to evaluate inflammatory markers in patients receiving pelvic radiation therapy and Pediococcus-based probioticsOpen
1541GCC1541GCC: Phase III Open-Label, Multicenter, Randomized Study of ASP2215 vs. Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 MutationOpen
1547GCCULTRASOUND-BASED BLADDER SCANNING FOR REPRODUCIBILITY OF BLADDER-FILLING DURING ABDOMINOPELVIC EXTERNAL BEAM RADIOTHERAPYOpen
1550GCCRandomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After ChemotherapyOpen
1554GCCA Phase 1/2 Study of INCB053914 in Subjects With Advanced MalignanciesOpen
1556GCCA Phase I Dose Escalation Open-Label Clinical Trial Evaluating the Safety and Efficacy of MAGE-A10c796T in Subjects with Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC).Open
1557GCCImpact of construal on demand for cigarettesOpen
1562GCCA Phase 1b / Randomized Phase 2a Trial of Indoximod in Combination with Idarubicin and Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Open
1563GCCMitigation of radiation pneumonitis and fibrosisOpen (affiliates only)
1564GCCPhase I trial of brentuximab vedotin combined with re-induction chemotherapy in patients with relapsed or refractory, CD30-expressing acute myeloid leukemia (AML).Open
1565GCCMulticenter phase 1/2 study of combination therapy with the DNA methyltransferase inhibitor decitabine and the poly ADP ribose polymerase (PARP) inhibitor talazoparib (BMN 673) for untreated acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or relapsed/refractory AMLOpen
1567GCCA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Open
1569GCCA Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung CancerOpen
1570GCCPhase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer Open
1571GCCPhase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node IrradiationOpen
1572GCC1572GCC: Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual MyelomaOpen
1578GCCPhase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed. NCI 9837, PhI-76Open
1579GCCA Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating AgentOpen
1583GCCA Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation with Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate_ GU002-10 Open
1590GCC1590GCC: A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid or Hematological MalignanciesOpen
1594GCCAN OPEN-LABEL, SINGLE-ARM, PHASE II STUDY OF PERTUZUMAB WITH HIGH-DOSE TRASTUZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM PROGRESSION POST-RADIOTHERAPY IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER (PATRICIA)Open
1600GCC1600GCC: GS-US-296-0101: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Andecaliximab (GS-5745) as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid TumorsOpen
1601GCCAn Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide ProphylaxisOpen
1607GCCA Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)Open
16100GCC16100GCC: A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma [CA209-743]Open
16101GCC16101GCC: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
16102GCC16102GCC: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell TransplantationOpen
16103GCCA Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL) Open
16105GCC16105GCC: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) [AFT-28]Open
16110GCC16110GCC: A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell TransplantationOpen
16111GCC16111GCC: A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) Open
16115GCCIntegration of Cancer Health Activities into African American ChurchesOpen (affiliates only)
16118GCC16118GCC: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD) Open
1611GCCPhase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma FusionOpen
1614GCC Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)Open
1618GCCCARDIAC MAGNETIC RESONANCE IMAGING AND BIOMARKER TESTING FOR EVALUATING CARDIAC INJURY RESULTING FROM RADIATION THERAPY IN LUNG AND BREAST CANCER: A PILOT STUDYOpen
1626GCCA Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation TherapyOpen
1629GCCRandomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Chemotherapy Naive stage IV Non-small Cell Lung CancerOpen
1630GCC1630GCC:A Pilot study of Zydelig in Patients with B-cell Malignancies as Post-Autologous Transplant Remission MaintenanceOpen
1632GCC1632GCC: A Phase 1/1b, Multicenter, Open-Label, Dose-Escalation Study of FT 2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 MutationOpen
1635GCC Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereo-tactic Ablative Body Radiotherapy (SAbR) Open
1638GCCA Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell CarcinomaOpen
1641GCCA Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaOpen
1642GCCA Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal CancerOpen
1649GCC1649GCC:Allogeneic hematopoietic stem cell transplantation for severe aplastic anemia and other bone marrow failure syndromes using G-CSF mobilized CD34+ selected hematopoietic precursor cells co-infused with a reduced dose of non-mobilized donor T-cells Open
1652GCCPhase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)Open
1654GCC1654GCC: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)Open
1657GCC9979 : Phase 1 and Pharmacology Study of Oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases Open
1662GCC1662GCC: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma - MK-3475-361Open
1665GCC1665GCC: An Umbrella Protocol for the Collection of Blood and Biological Samples from Patients with Established or Suspected Gastrointestinal Malignancies, Mesothelioma, and Normal Subjects to Be Used in Laboratory ResearchOpen
1666GCC1666GCC: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (with Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients with High-Risk Squamous Cell Carcinoma of the Oral CavityOpen
1671GCCA Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR AlterationsOpen
1676GCCA Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating AgentsOpen
1680GCC1680GCC: A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial CancerOpen
1682GCCA Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) [CA018001]Open
1683GCC1683GCC: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast CancerOpen
1685GCC Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the treatment of Oropharyngeal Cancer of the Head and Neck Open
1686GCC1686GCC: A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects with Relapsed/Refractory Aggressive B-Cell Non Hodgkin LymphomaOpen
1687GCCPARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life; A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer. Open
1693GCC-EU1693GCC-EU Compassionate use of ASP2215 in patient PBOpen
1695GCCUMGCCC Data and Biosample Repository and Maryland Cancer Survivorship CohortOpen
1704GCC1704GCC: A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine [15-102-14]Open
1707GCCC1707GCCC: An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaOpen
1708GCC1708GCC: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination DeficiencyOpen
1709GCC1709GCC: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin ChemotherapyOpen
1711GCCCNeoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue SarcomaOpen
1712GCC1712GCC: A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerOpen
1717GCCA Ketogenic Diet Pilot Study for Overweight Prostate Cancer Patients on Active SurveillanceOpen
1718GCCC-M1A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)Open
1718GCCC-S1Targeting CD200 with Samalizumab to Enhance Outcomes in Elderly Untreated Core-Binding Factor Acute Myeloid Leukemia [BAML-16-001-S1]Open
1718GCCC-S2Phase Ib/II Study of BI 836858 with Azacitidine in Previously Untreated AML Patients >60 Years With Unique Molecular Features [BAML-16-001-S2]Open
1718GCCC-S3A Phase II Study to Assess the Efficacy of the Treatment of IDH2 Mutant AML with Targeted IDH2 Inhibition and Subsequent Response-Driven Addition of Hypomethylating Agent Therapy [BAML-16-001-S3]Open
1718GCCC-S4A Phase 1b/2 Study of Entospletinib (ENTO) in Patients with Acute Myeloid Leukemia (AML) > Age 60 with Mixed Lineage Leukemia (MLL) Gene Re-arrangements and/or MLL-Partial Tandem Duplications (MLL-PTD)Open
1718GCCC-S5A Phase 2 Study of Entospletinib and Decitabine Targeting Mutant TP53 and or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia > Age 60 yearsOpen
1718GCCC-S6A Phase 2 Study of Entospletinib in NPM1 mutant/FLT3 ITD Wild Type AML Patients Age >= 60 yearsOpen
1720GCCCA Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients with FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) with Minimal Residual Disease (MRD)Open
1723GCCC1723GCCC: TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination DeficiencyOpen
1728GCCCA Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaNot Open
1732GCCBIO 300 Humanetics Corp # CL0101-01 – A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC) IND 119322Open
1754GCCCAssessment of the cognitive effects of chemotherapy in breast cancer patientsOpen
1758GCCA Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients Open
1759GCCCA Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell LymphomaOpen
1762GCCCExpanded Access of Sapacitabine for PEPOpen
1767GCCCOpen-Label Randomized Pilot Study To Assess The Safety, Tolerability And Antitumor Activity Of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone Or In Combination With Pembrolizumab In HLA-A2+ Subjects With NY-ESO-1 And/Or LAGE 1A Positive Relapsed And Refractory Multiple MyelomaOpen
1768GCCBiobehavioral Mechanisms of Breast Cancer Racial DisparitiesOpen
1784GCCCA Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 TrialOpen
30610CALGBPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and EtoposideOpen
341256Implementation of evidence-based cancer early detection in Black churchesOpen (affiliates only)
375044African American and Colo-rectal Cancer: A Multilevel Model to Assess Factors that may explain CRC Health DisparitiesOpen (affiliates only)
380462Behavioral Intervention to Reduce Breast Cancer Disparity in Under served KoreansOpen (affiliates only)
A011106ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III studyOpen
A011202A RANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF AXILLARY LYMPH NODE DISSECTION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPYOpen
A011401Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast CancerOpen (affiliates only)
A011502Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyOpen (affiliates only)
A081105ALCHEMIST: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)Open
A151216Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Open
AALL1231AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)Open
AALL1331AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)Open
AAML1331AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid. Open
AEWS1221AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaOpen
AHOD1331AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (Bv, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and AdolescentsOpen
APEC14B1APEC14B1: THE PROJECT: EVERYCHILD PROTOCOL: A REGISTRY, ELIGIBILITY SCREENING, BIOLOGY AND OUTCOME STUDYOpen
APEC1621APEC1621: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolOpen
E1910E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in AdultsOpen
E2112A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast CancerOpen
E4512ALCHEMIST: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
EA5142EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung CancersOpen
EAY-131EAY- 131 Molecular Analysis for Therapy Choice (MATCH) Open
G1T28-04Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and CarboplatinOpen (affiliates only)
GI001RANDOMIZED PHASE III STUDY OF FOCAL RADIATION THERAPY FOR UNRESECTABLE, LOCALIZED INTRAHEPATIC CHOLANGIOCARCINOMA Open
N1048N1048 (PROSPECT**): A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal ExcisionOpen
NHLBI-MDSA prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural HistoryOpen (affiliates only)
NRG-BN001RANDOMIZED PHASE II TRIAL OF HYPOFRACTIONATED DOSE-ESCALATED PHOTON IMRT OR PROTON BEAM THERAPY VERSUS CONVENTIONAL PHOTON IRRADIATION WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAOpen
NRG-BR002A Phase IIR/III Trial of Standard of Care with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerOpen
NRG-BR003NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Open
NRG-CC001A Randomized Phase III Trial Of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases Open
NRG-GU003A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT).Open
NRG-GY005Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)Open (affiliates only)
NRG-HN002A RANDOMIZED PHASE II TRIAL FOR PATIENTS WITH p16 POSITIVE, NON-SMOKING ASSOCIATED, LOCOREGIONALLY ADVANCED OROPHARYNGEAL CANCER Open (affiliates only)
NSABP-B-55NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib vs. Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyOpen
POLARISPOLARIS: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional StudyOpen (affiliates only)
PUMA-NER-1301A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)Open (affiliates only)
S0820S0820, A Double Blind Placebo-Controlled Trial of Eflornithine andSulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)Open
S1418A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant ChemotherapyOpen (affiliates only)
SWOG1207SWOG 1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine TherapyOpen
SWOG1400S1400 PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR SECOND LINE THERAPY OF SQUAMOUS CELL LUNG CANCEROpen
SWOG1400FS1400F: A PHASE II STUDY OF MEDI4736 (DURVALUMAB) PLUS TREMELIMUMAB AS THERAPY FOR PATIENTS WITH PREVIOUSLY TREATED ANTI-PD-1/PD-L1 RESISTANT STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP NON-MATCH SUB-STUDY)Open
SWOG1400GS1400G: A PHASE II STUDY OF TALAZOPARIB (BMN 673) IN PATIENTS WITH HOMOLOGOUS RECOMBINATION REPAIR DEFICIENCY POSITIVE STAGE IV SQUAMOUS CELL LUNG CANCER (LUNG-MAP SUB-STUDY)Open
SWOG1400IS1400I A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)Open